The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
An introduction to QT interval prolongation and non‐clinical approaches to assessing and reducing risk
Open accessAbstract
Owing to its association with Torsades de Pointes, drug‐induced QT interval prolongation has been and remains a significant hurdle to the development of safe, effective medicines. Genetic and pharmacological evidence highlighting the pivotal role the human ether‐a‐go‐go‐related gene (hERG) channel was a critical step in understanding how to start addressing this issue. It led to the development of hERG assays with the rapid throughput needed for the short timescales required in early drug discovery. The resulting volume of hERG data has fostered in silico models to help chemists design compounds with reduced hERG potency. In early drug discovery, a pragmatic approach based on exceeding a given potency value has been required to decide when a compound is likely to carry a low QT risk, to support its progression to late‐stage discovery. At this point, the in vivo efficacy and metabolism characteristics of the potential drug are generally defined, as well its safety profile, which includes usually a dog study to assess QT interval prolongation risk. The hERG and in vivo QT data, combined with the likely indication and the estimated free drug level for efficacy, are put together to assess the risk that the potential drug will prolong QT in man. Further data may be required to refine the risk assessment before making the major investment decisions for full development. The non‐clinical data are essential to inform decisions about compound progression and to optimize the design of clinical QT studies. This article is commented on by Guth and Rast, pp. 22–24 of this issue and is part of a themed section on QT safety. To view this issue visit http://www3.interscience.wiley.com/journal/121548564/issueyear?year=2010
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hammond, T. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00310-2 · Cited by 117
Self-citation
Cited by
Photocatalytic Late-Stage C–H Functionalization
Bellotti, P., Huang, H.-M., Faber, T., & Glorius, F. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00478 · Cited by 623
Laverty, H., Benson, C., Cartwright, E., Cross, M., Garland, C., Hammond, T., Holloway, C., McMahon, N., Milligan, J., Park, B., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01255.x · Cited by 363
Self-citationFermini, B., Hancox, J. C., Abi-Gerges, N., Bridgland-Taylor, M., Chaudhary, K. W., Colatsky, T., Correll, K., Crumb, W., Damiano, B., Erdemli, G., et al. (2016) · SLAS Discovery · doi:10.1177/1087057115594589 · Cited by 302
Self-citationNguyen, N., Nguyen, W., Nguyenton, B., Ratchada, P., Page, G., Miller, P. E., Ghetti, A., & Abi-Gerges, N. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.01073 · Cited by 75
Parameter Identifiability of Fundamental Pharmacodynamic Models
Janzén, D. L. I., Bergenholm, L., Jirstrand, M., Parkinson, J., Yates, J., Evans, N. D., & Chappell, M. J. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00590 · Cited by 44
Metadata
- Authors
- Pollard, C., Abi Gerges, N., Bridgland‐Taylor, M., Easter, A., Hammond, T., & Valentin, J.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2010-01
- Volume
- 159
- Issue
- 1
- Pages
- 12-21
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1491280455
- Cited by
- 160
- References
- 1
- FWCI
- 10.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An introduction to QT interval prolongation and non‐clinical approaches to assessing and reducing risk. https://app.cochat.ai/papers/10.1111/j.1476-5381.2009.00207.x
- The paper
- Pollard, C., Abi Gerges, N., Bridgland‐Taylor, M., Easter, A., Hammond, T., & Valentin, J. (2010). An introduction to QT interval prolongation and non‐clinical approaches to assessing and reducing risk. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2009.00207.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.